The predictive value of CK-MB on the curative effect of urokinase combined with LMWH calcium in AMI
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: Objective This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium.Methods AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH). CK-MB levels were measured using ELISA, and adverse reactions were recorded. The accuracy of CK-MB as a predictor was evaluated via ROC curve analysis and AUC.Results Before treatment, CK-MB levels were similar in both groups (p > 0.05). Post-treatment, levels were significantly lower in the combined group (p < 0.05). The combined group had a higher proportion of mild CK-MB elevation and lower moderate/severe elevations (p < 0.05). Adverse reaction rates were similar (p > 0.05). The combined treatment group showed higher effectiveness (p < 0.05), with better sensitivity (94%) and specificity (82%) than the urokinase group (sensitivity 89%, specificity 78%).Conclusion CK-MB is a valuable predictor for evaluating the efficacy of urokinase plus LMWH in AMI treatment, offering advantages in reducing CK-MB levels and improving outcomes.
Source: Biomarkers in Medicine
Authors: Hongbin Tang, Yong Liu, Yabing Yu, Jun Zhou, Jiaomei Yang
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4404655604